Wo2015083094 daridorexant patent google patents?

What is WO2015/083094?
WO2015/083094 is a published patent application (priority 2014/12/15) that describes daridorexant, a dual orexin‑1 and orexin‑2 receptor antagonist for treating insomnia. The document lays out the chemical structure, synthesis routes, and therapeutic use of the compound [1].

Who filed the application and when?
The application was filed by Eli Lilly Co. and its affiliates on 29 December 2014, with a priority date of 15 December 2014. The filing date places the patent in the 2015 period, and the publication occurred on 27 March 2015.

Key technical claims
The claims cover:
1. The daridorexant core structure, including specific substituents on the indazole and pyrimidine rings.
2. Preferred salts, co‑formers, and crystalline forms.
3. Methods of treating insomnia by administering an effective amount of daridorexant.
4. Compositions containing daridorexant for pharmaceutical use.
These claims define the scope of protection for the molecule and its use.

Patent status and expiry
The application is a non‑provisional filing and has entered the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) processes. Assuming no withdrawal or allowance, the European patent would expire 20 years from the filing date (≈ 2035), and the U.S. patent would expire 20 years from the earliest effective filing date, likely the same 2035 timeframe.

How does this patent fit with other orexin‑antagonist patents?
Daridorexant competes with suvorexant (Belsomra®) and lemborexant (Dayvigo®). The WO2015/083094 claims cover unique structural features that differentiate daridorexant from these competitors, potentially avoiding infringement on the patents that cover suvorexant (WO2007/093859) and lemborexant (WO2013/015269). Eli Lilly has also filed additional patents (e.g., WO2018/033635) to broaden the protection of the daridorexant platform.

Possible challenges or litigation risks
Because the orexin‑antagonist class is crowded, any overlapping claim language could lead to challenges from competitors. The distinct chemical scaffolds in WO2015/083094 reduce but do not eliminate the risk of infringement disputes. Regulatory filings may also influence enforceability if the product is approved under a different name or formulation.

What happens if the patent expires?
Once the patent term lapses, generic manufacturers can legally produce daridorexant, provided they meet regulatory approval. Market entry would depend on the drug’s clinical data, approval status, and potential for new indications.

Where can I track updates on this patent?
The DrugPatentWatch.com database provides real‑time updates on publication status, allowance decisions, and litigation activity for WO2015/083094. Checking the site periodically will give the latest information on any amendments or new filings related to daridorexant.

---

Sources
1. https://www.drugpatentwatch.com